DEBORAH MEWBOURNE: Open Payments
NPI 1538397633 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,733 in 73 payments from 18 companies in 2025. Trend: 2023 $1,780 · 2024 $1,765 · 2025 $1,733
Food & beverage: $1,733
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $355 |
| Novartis Pharmaceuticals Corporation | 16 | $276 |
| ABBVIE INC. | 10 | $205 |
| AstraZeneca Pharmaceuticals LP | 5 | $191 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $156 |
| Lilly USA, LLC | 5 | $80 |
| Genmab U.S., Inc. | 3 | $68 |
| Daiichi Sankyo Inc. | 4 | $64 |
| PFIZER INC. | 3 | $61 |
| Aveo Pharmaceuticals, Inc. | 3 | $60 |
Products named: RYBREVANT, EPKINLY, Nubeqa, CALQUENCE, SCEMBLIX, VERZENIO, VENCLEXTA, KISQALI.
Industry payments across OK — which companies pay providers there.
